Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRASG12C and ARS compounds

被引:22
作者
Khrenova, Maria G. [1 ,2 ]
Kulakova, Anna M. [1 ]
Nemukhin, Alexander, V [1 ,3 ]
机构
[1] Lomonosov Moscow State Univ, Dept Chem, Moscow 119991, Russia
[2] Russian Acad Sci, Res Ctr Biotechnol, Bach Inst Biochem, Moscow 119071, Russia
[3] Russian Acad Sci, Emanuel Inst Biochem Phys, Moscow 119334, Russia
基金
俄罗斯科学基金会;
关键词
FORCE-FIELD; CRYSTAL-STRUCTURE; ACTIVE-SITE; RAS; MOLECULES; SOLVATION; MUTANT; MECHANISM; ENERGIES; COMPLEX;
D O I
10.1039/d0ob00071j
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The use of selective covalent inhibitors with low binding affinity and high reactivity with the target enzyme is a promising way to solve a long-standing problem of the "undruggable" RAS-like proteins. Specifically, compounds of the ARS family that prevent the activation of the GDP-bound G12C mutant of Kirsten RAS (KRAS) are in the focus of recent experimental research. We report the first computational characterization of the entire reaction mechanism of the covalent binding of ARS-853 to the KRAS(G12C)center dot GDP complex. The application of molecular dynamics, molecular docking and quantum mechanics/molecular mechanics approaches allowed us to model the inhibitor binding to the protein and the chemical reaction of ARS-853 with Cys12 in the enzyme binding site. We estimated a full set of kinetic constants and carried out numerical kinetic analysis of the process. Thus, we were able to compare directly the physicochemical parameters of the reaction obtained in silico and the macroscopic parameters observed in experimental studies. From our computational results, we explain the observed unusual dependence of the rate constant of covalent complex formation, k(obs), on the ARS concentration. The latter depends both on the non-covalent binding step with the equilibrium constant, Ki, and on the rate constant of covalent adduct formation, k(inact). The calculated ratio k(inact)/K-i = 213 M-1 s(-1) reproduces the corresponding experimental value of 250 +/- 30 M-1 s(-1) for the interaction of ARS-853 with KRAS(G12C). Electron density analysis in the reactive region demonstrates that covalent bond formation occurs efficiently according to the Michael addition mechanism, which assumes the activation of the CvC bond of ARS-853 by a water molecule and Lys16 in the binding site of KRAS(G12C). We also refine the k(inact) and K-i constants of the ARS-107 compound, which shares common features with ARS-853, and show that the decrease in the k(inact)/K-i ratio in the case of ARS-107 is explained by changes in both K-i and k(inact) constants.
引用
收藏
页码:3069 / 3081
页数:13
相关论文
共 4 条
  • [1] Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor
    Wijeratne, Aruna
    Xiao, Junpeng
    Reutter, Christopher
    Furness, Kelly W.
    Leon, Rebecca
    Zia-Ebrahimi, Mohammad
    Cavitt, Rachel N.
    Strelow, John M.
    Van Horn, Robert D.
    Peng, Sheng-Bin
    Barda, David A.
    Engler, Thomas A.
    Chalmers, Michael J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (06): : 557 - 562
  • [2] Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C
    Li, Amin
    Li, Sujing
    Wang, Peng
    Dang, Chaojie
    Fan, Xinrui
    Chen, Mengran
    Liu, Dan
    Li, Fu
    Liu, Huan
    Zhang, Wei
    Wang, Yanping
    Wang, Yinxiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 2422 - 2436
  • [3] JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors
    Lorthiois, Edwige
    Gerspacher, Marc
    Beyer, Kim S.
    Vaupel, Andrea
    Leblanc, Catherine
    Stringer, Rowan
    Weiss, Andreas
    Wilcken, Rainer
    Guthy, Daniel A.
    Lingel, Andreas
    Bomio-Confaglia, Claudio
    Machauer, Rainer
    Rigollier, Pascal
    Ottl, Johannes
    Arz, Dorothee
    Bernet, Pascal
    Desjonqueres, Gaelle
    Dussauge, Solene
    Kazic-Legueux, Malika
    Lozac'h, Marie-Anne
    Mura, Christophe
    Sorge, Mickael
    Todorov, Milen
    Warin, Nicolas
    Zink, Florence
    Voshol, Hans
    Zecri, Frederic J.
    Sedrani, Richard C.
    Ostermann, Nils
    Brachmann, Saskia M.
    Cotesta, Simona
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (24) : 16173 - 16203
  • [4] Revealing the mechanism of action of a fi rst-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31 P NMR
    Sharma, Alok K.
    Pei, Jun
    Yang, Yue
    Dyba, Marcin
    Smith, Brian
    Rabara, Dana
    Larsen, Erik K.
    Lightstone, Felice C.
    Esposito, Dominic
    Stephen, Andrew G.
    Wang, Bin
    Beltran, Pedro J.
    Wallace, Eli
    Nissley, Dwight V.
    McCormick, Frank
    Maciag, Anna E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (02)